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Tbjective: Destination therapy experience using long-term left ventricular assist
evices was analyzed relative to the benchmark Randomized Evaluation of Me-
hanical Assistance for the Treatment of Congestive Heart Failure trial to evaluate
he potential for improving outcomes with this groundbreaking therapy for advanced
eart failure.
ethods: The largest single-center experience with destination therapy in the United
tates (Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT) was
etrospectively analyzed. All destination therapy recipients (n  23) presented with
hronic, advanced heart failure, meeting indications for destination therapy adopted
rom the Randomized Evaluation of Mechanical Assistance for the Treatment of
ongestive Heart Failure trial. All received HeartMate left ventricular assist devices
Thoratec Corp, Pleasanton, Calif), with 87% receiving an improved XVE model.
dvanced practice guidelines were implemented using a multidisciplinary ap-
roach. Survivals (Kaplan–Meier, log-rank analyses) and adverse events (Poisson
egression) were compared with those of the Randomized Evaluation of Mechanical
ssistance for the Treatment of Congestive Heart Failure left ventricular assist
evice group (n  68).
esults: Survival in the destination therapy group was significantly increased (P 
007), with an overall reduction in mortality of 66%. The 2-year survival was 77%
or destination therapy compared with 29% for the Randomized Evaluation of
echanical Assistance for the Treatment of Congestive Heart Failure left ventric-
lar assist device group (P  .0001). The 1-year survival was 77% for destination
herapy compared with the Randomized Evaluation of Mechanical Assistance for
he Treatment of Congestive Heart Failure left ventricular assist device rate of 52%
P  .036). Adverse events decreased by 38% (3.90 per patient-year in the
estination therapy group compared with the Randomized Evaluation of Mechanical
ssistance for the Treatment of Congestive Heart Failure left ventricular assist
evice rate of 6.32). Factors related to severity of illness met Randomized Evalu-
tion of Mechanical Assistance for the Treatment of Congestive Heart Failure-like
riteria for both groups.
onclusions: This analysis provides evidence that long-term destination therapy can
e improved well beyond the pioneering experience of the Randomized Evaluation
f Mechanical Assistance for the Treatment of Congestive Heart Failure trial. With
ontinued evolution of devices, management, and patient selection, outcomes ap-
roaching those of heart transplantation may be possible.
he Journal of Thoracic and Cardiovascular Surgery ● Volume 135, Number 6 1353
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CSPeart failure has become a major public health con-
cern, with an incidence of 4.9 million cases in the
United States and 550,000 new cases every year.1
eart failure is generally progressive, ultimately reaching
n advanced end stage requiring organ replacement or sub-
titution. Heart transplantation is a standard of care, but the
vailability of donor hearts has leveled at 2100 per year,1
hich is well short of projected needs.
Mechanical circulatory support (MCS) offers hope for the
reatment of advanced heart failure. MCS has been used suc-
essfully over short to medium-term durations of support for
ridging to heart transplantation.2,3 As favorable outcomes
ave been observed over progressively longer durations of
upport with left ventricular assist devices (LVADs), interest
as grown in using these devices for the long-term treatment of
eart failure.4
The Randomized Evaluation of Mechanical Assistance for
he Treatment of Congestive Heart Failure (REMATCH) trial
valuated the efficacy and safety of long-term support with the
eartMate VE LVAD (Thoratec Corp, Pleasanton, Calif) com-
ared with optimal medical management (OMM) in patients
ith advanced, chronic heart failure New York Heart Associ-
tion class IV who were unable to undergo transplantation.
Evidence of superior survival with acceptable safety and
uality of life led to the first Food and Drug Administration
pproval in 2002 of LVADs for long-term destination therapy
DT) with the HeartMate models VE and XVE. The evidence
as been compelling enough to justify reimbursement from pay-
rs, including the Centers for Medicare and Medicaid Services.
The initial report of the REMATCH trial results identi-
ed a significant survival benefit of LVAD therapy com-
ared with OMM.5 Survivorship at 1 year of 52% in the
VAD arm compared favorably with 25% in the OMM
roup. At 2 years, survival was 23% with an LVAD,
hereas survival was only 8% with OMM. Overall, there
as a 48% reduction in the risk of death from any cause in
he LVAD arm compared with the OMM group. In addition,
uality of life was better with an LVAD than OMM.
Despite the remarkable impact on survival, the greatest
f any heart failure therapy previously studied, LVAD ther-
py during REMATCH was associated with considerable
ortality and morbidity. This is not too surprising given the
ioneering initiatives with a new therapy in a high-risk
atient population. Nevertheless, for DT with LVADs to
ucceed, improvements will be necessary with (1) devices,
2) patient management, and (3) patient selection.
The overall experience with DT since the REMATCH trial
emains modest. Only a few centers have individual experience
eyond 10 patients. To date, there has been only 1 publication
eporting DT outcomes outside of the REMATCH trial.6
iven the complexities of this therapy with a significant learn-
ng curve, information about performance is vital for improve-
ent and responsible dissemination. t
354 The Journal of Thoracic and Cardiovascular Surgery ● JunThis study was conducted to evaluate DT outcomes
ithin the largest single-center experience to date to better
nderstand the potential for improving outcomes with this
volving therapy for advanced heart failure.
aterials and Methods
atient Selection
atients receiving DT from the Utah Artificial Heart Program at
DS Hospital, Salt Lake City, Utah (LDSH DT cohort) were
tudied and compared with LVAD recipients from the REMATCH
rial. The REMATCH cohort consisted of the 68 patients from the
VAD arm of the REMATCH trial with 89 patient-years of
xperience. The LDSH DT cohort consisted of all patients in the
T LVAD group not randomized to the LVAD arm of the
EMATCH trial and receiving an implant before March 14, 2005:
total of 23 patients with 26.8 patient-years of experience.
The selection of patients receiving DT incorporated REMATCH
rial enrollment criteria,7 Food and Drug Administration-approved
ndications, and Centers for Medicare and Medicaid Services qual-
fications.8 Inclusion criteria included (1) New York Heart Asso-
iation class IV end-stage heart failure during the last 3 months
espite OMM, (2) maximum oxygen consumption (VO2 max) of
ess than 12 mL/kg1/min1 (reduced from REMATCH criteria of
4 mL/kg1/min1) or dependence on intravenous inotropes, and
3) left ventricular ejection fraction less than 25%. Exclusion
riteria included (1) eligibility for heart transplantation; (2) the
resence of comorbid factors, other than those due to heart failure,
recluding survival of at least 2 years; and (3) body size too small
or the HeartMate VE or XVE LVAD (body surface area 1.6 m2).
All patients who were in the LDSH DT cohort fit REMATCH
ualifications with the exception of 1 patient who would have been
xcluded from the REMATCH trial by the presence of chronic
enal failure requiring dialysis.
Patients from LDSH who were randomized to the LVAD arm
f the REMATCH trial remained a part of the REMATCH cohort
nd were not included in the LDSH DT group.
Appropriate institutional review board approvals were obtained.
anagement
T recipients were guided through the complex management process
haracteristic of DT in this era by a multidisciplinary team located
oth at LDSH and in remote locations where the patients lived.
Candidacy was established after conducting reviews from mul-
Abbreviations and Acronyms
CVA  cerebrovascular accident
DT  destination therapy
LVAD  left ventricular assist device
OMM  optimal medical management
MCS mechanical circulatory support
REMATCH Randomized Evaluation of Mechanical
Assistance for the Treatment of
Congestive Heart Failure
VO2 max maximum oxygen consumptioniple perspectives in consideration of surgical issues, heart failure/
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Pransplant/diagnostic cardiology issues, critical care challenges,
edical reserve, physical capacity/conditioning, cognitive capac-
ty, psychosocial support, and factors affecting long-term outpa-
ient support.
Preoperative optimization of the patient was undertaken (with
edical therapy, critical care support, and monitoring or intraaor-
ic balloon pump use) when it was possible to do so without
ntroducing additional risk of further decline.
HeartMate LVADs (Thoratec Corp) were used in all patients.
wenty patients (87%) received the improved XVE, and 3 early
atients (13%) received the VE.
Field-wide standards of care and guidelines for clinical practice
ere incorporated whenever available. This included Infection
ontrol Guidelines (REMATCH Surgical Committee, available
rom Thoratec) and Advanced Practice Guidelines for HeartMate
estination Therapy (Heart Hope Initiative, Park City Work
roup, and Thoratec Corporation).
nalysis
npaired t tests were used to examine continuous data. Fisher
ABLE 1. Baseline characteristics
REMATC
General
Age (y) 66
Male sex (%) 7
Heart failure
Ischemic cause (%) 7
NYHA class (IV/IIIb) 6
VO2 max (mL/kg/min), as obtainable 9.1  2.
LVEF (%EF) 17
Medications
Digoxin (%) 8
Loop diuretics (%) 9
Spironolactone (%) 3
ACE inhibitors (%) 6
A-II antagonists (%) 1
Amiodarone (%) 4
Beta-blockers (%) 2
Organ function
Serum creatinine (mmol/L) 1.7
Serum sodium (mmol/L) 135
Hemodynamic status
Systolic BP (mm Hg) 101
Diastolic BP (mm Hg) 61
PCWP (mm Hg) 25
CI (L*min^-1*m^-2) 1.9
Heart rate (beats/min) 84
PVR (Wood Units) 3.4
IABP (%) 1
IV inotropes (%) 6
alues are listed as mean  standard deviation or as indicated. LDSH DT
YHA, New York Heart Association; LVEF, left ventricular ejection fraction
ndex; PVR, pulmonary vascular resistance; VO2 max, maximum oxygen con
Statistical significance.xact tests were performed on discrete data. Probability was l
The Journal of Thoracic-tailed in both cases. Survival was analyzed by using the Kaplan–
eier product limit method. Log-rank analysis was used to deter-
ine differences in survival distributions. Impact on mortality was
nalyzed using a Cox proportional hazard model. Poisson regression
ith 95% confidence intervals was used to analyze adverse event
ates.
Definitions for adverse events were the same as for the
EMATCH trial.
esults
atient Characteristics
atients in the 2 groups had similar baseline characteristics
Table 1). Notably, both REMATCH and LDSH DT groups
ad very advanced heart failure as manifested by preexist-
ng New York Heart Association class IV status (66/68
atients in the REMATCH group, 23/23 patients in the
DSH DT group), intravenous inotrope requirement (65%
n the REMATCH group and 61% in the LDSH DT group),
68) LDSH DT (n 23) P value
68 8.7 .4360
91% .2204
87% .5456
23/0 1.0000
37) 10.6  1.4 (n 13) .0163*
19 4.4 .4102
57% .0056*
91% .5972
43% .4566
39% .0881
22% .1710
30% .2305
22% 1.0000
5 1.9 1.2 .3153
139 5.8 .0079*
108 10 .0533
61 9 1.0000
20 7.8 .0196*
9 2.2 0.51 .1684
81 13 .4170
3.2 1.6 .6382
13% 1.0000
61% .8041
Hospital destination therapy group; ACE, angiotensin-converting enzyme;
blood pressure; PCWP, pulmonary capillary wedge pressure; CI, cardiac
tion; IABP, intraaortic balloon pump; EF, ejection fraction; IV, intravenous.H (n
 9.1
8%
8%
6/2
0 (n
 5.2
7%
6%
4%
2%
0%
5%
4%
 0.6
 5.4
 15
 10
 9.9
 0.9
 16
 1.8
0%
5%
, LDS
; BP,
sumpow ejection fractions, and compromised hemodynamics.
and Cardiovascular Surgery ● Volume 135, Number 6 1355
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1
CSPThe comorbid factor of advanced age is reflected in
oth groups to a similar degree (average age 66 years in
he REMATCH group and 68 years in the LDSH DT
roup).
Although all patients met REMATCH-like criteria with
ery advanced heart failure, some preoperative parameters
ndicate that the LDSH DT group may have been in slightly
etter condition at the time of implantation than the
EMATCH group. Systolic blood pressure was higher (108
s 101 mm Hg, LDSH DT vs REMATCH), pulmonary
apillary wedge pressure was lower (20 vs 25 mm Hg), and
erum sodium was higher (139 vs 135 mmol/L) in the
DSH DT group (Table 1). VO2 max was modestly higher
n the LDSH DT group (10.6 1.4 mL/kg/min vs 9.1 2.0
L/kg/min, LDSH DT vs REMATCH), although the value
or both groups was considerably less than 14 mL/kg/min
sed as the cutoff in the REMATCH trial or 12 mL/kg/min
ith current selection guidelines.
On the other hand, intravenous inotrope requirement was
omparable (61% use in the LDSH DT group vs 65% in the
EMATCH group). The same is true with preoperative
ntraaortic balloon pump use (13% incidence in the LDSH
T group vs 10% in the REMATCH group).
Comorbidities precluding transplant ineligibility in the
DSH DT group included advanced age (70%), diabetes/
therosclerotic peripheral vascular disease (9%), history of
alignancy (9%), renal failure/insufficiency (9%), and obe-
ity (4%). Advanced age accounted for the majority (70%),
igure 1. LDSH DT versus REMATCH LVAD. One year post-
mplant: REMATCH, 52%  6%; LDS DT, 77%  10%; P  .0355.
wo years post-implant: REMATCH, 29%  6%; LDS DT, 77% 
0%; P < .0001. LDSH, LDS Hospital; LVAD, left ventricular assist
evice.nd most of those were aged 70 years or more. In general, p
356 The Journal of Thoracic and Cardiovascular Surgery ● Junhese patients would not likely be considered good trans-
lant candidates anywhere, even in centers in which trans-
lantation with advanced age is being promoted.
urvival
aplan–Meier survival curves are displayed in Figure 1. A
omparison of survival over the entire 2-year period dem-
nstrated a highly significant improvement of LDSH DT
ver the REMATCH LVAD group (P  .007). Overall,
here was a 66% reduction in mortality with LSDH DT
ompared with REMATCH.
At 1 year, the LDSH DT group had a survival of 77%
ompared with 52% in the REMATCH LVAD group (P 
0355). The 2-year survival of the LDSH DT group was
7% compared with 29% for the REMATCH group (P 
0006). At 2 years, this represents a 2.6-fold improvement in
urvival.
ortality and Causes of Death
auses of death for the 2 groups are listed in Table 2. In the
EMATCH LVAD group, sepsis was the leading cause of
eath (37%), followed by LVAD failure (19%).9 Perioper-
tive mortality (considered as death before discharge) was
1%. Once discharged, there were 0.48 deaths per
atient-year.
Among patients in the LDSH DT group, perioperative
ortality was 8.7% (2/23 patients), accounting for approx-
mately one fourth of all deaths. Multiple organ dysfunction
as the cause in both cases. Once discharged, death oc-
urred at a rate of 0.19 deaths per patient-year. Causes of
eath long term (5/23 patients) were related to LVAD
ailure (n  2), infection (n  2), and malignancy (n  1).
Relative to the REMATCH experience, perioperative
ortality in the LDSH DT group was reduced 3.5-fold
from 31% to 8.7%). The rate of death after discharge was
ecreased by a factor of 2.5 (from 0.48 to 0.19 deaths per
ABLE 2. Causes of death
REMATCH
(n  68)
LDSH DT
(n  23)
epsis 21 2
VAD failure 11 2
erebrovascular 7 0
ultiple organ failure 7 2
ardiovascular (RHF, arrhythmia) 6 0
ulmonary embolism 2 0
nknown/other 2 0
alignancy 0 1
erioperative bleeding 1 0
otal 57 7
DSH DT, LDS Hospital destination therapy group; LVAD, left ventricular
ssist device; RHF, right-sided heart failure.atient-year).
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PMore detail about the LDSH DT deaths appears in Table 3.
dditional review offers insight useful for improving
utcomes.
Perioperative deaths. Both of the LDSH DT periopera-
ive deaths involved acute hemodynamic decompensation
reoperatively, superimposed on chronic, advanced heart
ailure. Before the patients’ operations, perfusion and end-
rgan function had deteriorated requiring heroic attempts to
tabilize with intensive care management, hemodynamic
onitoring, intubation, and escalating inotropes. Both pa-
ients went to the operating room for “salvage” rather than
lective placement of an LVAD for DT.
Before the acute events, both patients were chronically
ompromised enough to meet indications for DT and had
een considered “stable.” In retrospect, however, they had
eceptively limited margins of reserve and were at risk for
apid acute deterioration.
Long-term deaths. Device end-of-life LVAD failure led
o 2 of the long-term deaths. One death occurred after 4.6
ears of support. At a third pump replacement (all for
echanical failures), this patient experienced a periopera-
ive cerebrovascular accident (CVA), believed to be the
esult of embolization of fibrous tissue from the left ven-
ricular cannula insertion site, dislodged during LVAD re-
oval. The second death occurred at 3.3 total years support
n a patient whose second pump failed. Replacement was
ot attempted given an unacceptable benefit-to-risk assess-
ent in an 80-year-old patient who was beginning to de-
line with age-related end-of-life issues.
Infection contributed to the death of 2 patients, the first at
.6 months. One week after presenting with bacteremia, the
atient had a multi-infarct CVA believed to be related to
mbolization of fibrinous material from his LVAD blood
ontacting surfaces noted at autopsy.
LVAD infection contributed indirectly to a second death
t 10 months. Poor wound healing with delayed breakdown
ed to an LVAD surface infection after discharge. The
pocket” infection was controlled with high-potency,
ustained-release antibiotic beads.10 However, the patient
ABLE 3. LDS Hospital destination therapy causes of deat
ge and
ender Discharged
Support
duration
70 M No 25 d Multiple organ failure
73 M No 82 d Multiple organ failure
77 M Yes 229 d/7.6 mo LVAD infection (causing em
73 M Yes 297 d/9.9 mo LVAD infection (resolved, bu
74 M Yes 931 d/2.6 y Colon cancer
77 M Yes 1188 d/3.3 y LVAD failure (on second pu
76 M Yes 1677 d/4.6 y LVAD failure (requiring third
VAD, Left ventricular assist device; HF, heart failure; CVA, cerebrovascuever regained physical and emotional well-being, and died L
The Journal of Thoracicith progressive “failure to thrive.” Risks for this included
reexisting cachexia/malnutrition and severe decondition-
ng compounded by limited personal and social-support
apacity to maintain a strong will to live.
Comorbid disease in the form of colon cancer, not de-
ectable at the time of LVAD implantation, led to a death at
.6 years of support.
dverse Events
dverse events overall, presented in Table 4, were signifi-
antly improved in the LDSH DT cohort, reduced to two
hirds the rate of the REMATCH LVAD group (rate ratio
.62, 95% confidence interval: 0.50-0.79).
Among the general adverse events, the 74% lower rate of
epsis (rate ratio 0.26, 0.08-0.85) was significantly less in
he LDSH DT cohort than in the REMATCH cohort,
hereas a 65% lower rate of local infection (rate ratio 0.35,
.11-1.17) trended toward statistical significance. An 85%
eduction in the frequency of late bleeding (rate ratio 0.15,
.04-0.62) was noted in the LDSH DT group compared with
he REMATCH group. The neurologic events in the LDSH
T group (no difference in rate compared with
EMATCH) were all reversible, leaving no residual except
or 1 patient who had a CVA due to infection-related
mbolism that resulted in death (as noted above). Thus,
eriously compromising strokes occurred at a rate of only
.04 per patient-year in the LDSH DT group.
In regard to LVAD-related adverse events, perioperative
leeding was less in the LDSH DT group (rate ratio 0.22,
.05-0.92). Right-sided heart failure after LVAD placement
0.09 per patient-year for LDSH DT vs 0.16 for
EMATCH) was not statistically different. Temporary right
entricular assist devices were used in 10% of all LDSH DT
mplants, whether initial or replacement.
The rate of LVAD malfunction was significantly lower
rate ratio 0.26, 0.11-0.66) with the more recent LDSH DT
xperience than with REMATCH. There were no cata-
trophic LVAD failures. It is relevant to note the use of the
mproved HeartMate XVE in 87% of the patients in the
detail
Cause of death
CVA)
tributing to inability to recover from HF-related failure to thrive)
p replacement, complicated by perioperative embolic CVA)
cident; LDSH DT, LDS Hospital destination therapy group.h in
bolic
t con
mp)
pumDSH DT group compared with the REMATCH group,
and Cardiovascular Surgery ● Volume 135, Number 6 1357
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1
CSPuring which the earlier model, the HeartMate VE, was
sed exclusively. It is not possible, given limited numbers,
o determine how this has translated into greater durability.
Still, LVAD replacement was required in the LDSH DT
roup 7 times, in 5 patients, all as a result of mechanical
ailure (0.26 LVAD replacements per patient-year of sup-
ort). No devices failed until after the first 12 months. By 24
onths, 50% of LVADs had failed. Perioperative mortality
ith replacement was 14%.
iscussion
istorical Context
he REMATCH trial initiated a new era in the field of
CS. REMATCH was a groundbreaking, innovative trial
ielding results that have served as a benchmark for long-
erm, so-called DT with LVADs. The results are remark-
ble, considering the revolutionary nature of this initial
xperience with long-term LVADs in the population with
he highest risk of heart failure studied up to that time.
It is important that DT outcomes be improved beyond the
riginal performance of REMATCH. Although the REMATCH
rial demonstrated a greater impact of LVADs on survival
ABLE 4. Adverse events
ny adverse event
eneral AEs
Sepsis
Local infection
Bleeding, non-neurologic
Neurologic dysfunction
Renal failure
Hepatic failure
Serious psychiatric disease
Other AE
Supraventricular arrhythmia
Ventricular arrhythmia
Syncope
Cardiac arrest
Nonperioperative MI
Peripheral thrombosis or TE
Es associated with LVAD
Perioperative bleeding
Right-sided heart failure after LVAD
Perioperative MI
Malfunction of LVAD
Catastrophic failure of LVAD
Infection of drive-line tract or pocket
Infection of pump interior, inflow tract, or outflow tract
Thrombosis in LVAD
E, Adverse event; MI, myocardial infarction; TE, thromboembolism; LVAD,
I, confidence interval. *Statistical significance.han any previously evaluated therapy, the mortality and o
358 The Journal of Thoracic and Cardiovascular Surgery ● Junorbidity were substantial. The mortality (77% at 2 years
hen first reported), resulting mainly from infection and
evice failure, became a clear target for improvement, as
as the morbidity of adverse events.
Much was learned during the REMATCH trial about pa-
ient selection,11 surgical technique,12 and patient manage-
ent.13,14 This knowledge has been coalesced into advanced
ractice guidelines. In addition, changes to the HeartMate
VAD have been made to improve reliability.6,9,15
Although, in general, outcomes with MCS have im-
roved with experience,16 it is important to establish that
T can be improved. The first indication of such was the
nding of improved survival in the LVAD arm over the
ourse of the REMATCH trial.9 Two-year survival with
VADs in the last half of the trial was 38% compared with
1% in the first half of the trial, whereas there was no
hange in survival with medical management. It was sug-
ested that advances in patient management and LVAD
echnology led to this improvement.
The only other report to date of experience beyond
EMATCH confirms an ongoing trend toward improved
ATCH (n  68) LDSH DT (n  23)
ents/patient-y events/patient-y Rate ratio (95% CI)
6.32 3.90 0.62 (0.50-0.79)*
0.51 0.13 0.26 (0.08-0.85)*
0.38 0.13 0.35 (0.11-1.17)
0.6 0.09 0.15 (0.04-0.62)*
0.44 0.44 1.02 (0.5-2.09)
0.22 0.22 1.02 (0.37-2.81)
0.03 0.00 —
0.03 0.00 —
1.35 1.73 1.30 (0.89-1.89)
0.12 0.04 0.38 (0.05-3.06)
0.23 0.09 0.38 (0.09-1.66)
0.09 0.04 0.51 (0.06-4.23)
0.09 0.00 —
0.02 0.00 —
0.09 0.18 2.04 (0.58-7.23)
0.41 0.09 0.22 (0.05-0.92)*
0.16 0.09 0.56 (0.12-2.51)
0 0.00 —
0.85 0.22 0.26 (0.11-0.66)*
0.1 0.00 —
0.35 0.44 1.27 (0.61-2.67)
0.19 0.00 —
0.04 0.00 —
entricular assist device; LDSH DT, LDS Hospital destination therapy group;REM
ev
left vutcomes in experienced centers.6
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Pmportance of the Present Study
he results reported in this study provide strong affirmation
f the potential for improving outcomes with long-term
VAD DT. Further, the magnitude of improvement sets
ew standards on which to create realistic goals for the
uture of DT as essential processes of care mature.
Three major contributors to improving DT outcomes
nclude (1) patient management, (2) LVAD device improve-
ents, and (3) patient selection. Although all 3 of these are
ikely to have played some role in the present experience,
e believe the importance of patient management and pa-
ient selection cannot be underemphasized. This is consis-
ent with the present state of the art, in which the “steep
earning curve” must be addressed by a more rapid evolu-
ion of DT management and more immediate refinement of
atient selection (even within the overall constraint of a
EMATCH-like population with very advanced heart fail-
re), whereas improvements in devices will be slower to
aterialize.
Patient selection. The demographics of the LDSH DT
roup clearly meet REMATCH-like indications of a popu-
ation with advanced heart failure. Thus, we have not
volved beyond REMATCH-like indications. The experi-
nce within this study may indicate a small trend toward
electing slightly less-compromised patients within this
roup of candidates with advanced heart failure.
All of the perioperative mortalities occurred in patients
n whom we tried to intervene too late in their course. We
ow consider urgent use of DT, in a salvage-like manner, to
e highly lethal or to lead to serious perioperative morbid-
ty. Our patient selection has subsequently evolved to ex-
reme caution and even exclusion with such patients. It will
e important, as further experience accrues, to improve the
riteria for selecting patients to undergo DT with formal risk
nalysis tools, as has been described for bridging to trans-
lantation,17 to avoid DT when likely to be futile.
We believe timing is critical to outcomes. Judging from
he steep mortality in the early stages of the REMATCH
ontrol medical arm (5% mortality per week), it takes
nly a few weeks beyond the first diagnosis as a
EMATCH-like candidate to subject the patient-in-waiting
o an undesirable 15% to 20% additional risk of mortality
hile waiting.
Beyond those risk factors previously identified for bridg-
ng to transplantation, we consider important perioperative
isk factors relevant to this patient population to include
avages of chronic decline, deconditioning, and malnutri-
ion. Factors particularly prevalent in the DT population that
e believe affect long-term outcomes include age-related
ssues (cognition, dexterity, comorbid diseases) and social
upport.
Left ventricular assist device improvements. The Heart-
ate technology used in this study is good technology18 d
The Journal of Thoracicnd continues to undergo important improvements. Al-
hough the full impact of the modifications incorporated into
he XVE model cannot be determined by this study, we
ontinue to experience end-of-life device failures requiring
eplacement on average between 18 and 24 months. The
pparent reduction in LVAD failure-related mortality in our
xperience compared with the REMATCH trial is largely
ue to improved management with a reduction of mortality
ith device replacement from 30% to 40% to approximately
5%. Improved durability beyond that of the present Heart-
ate XVE is essential to further reduce the risks associated
ith device failure. It is hoped that trials of other devices
sing the HeartMate as a control will provide further
nowledge.
Management. We approach DT with the perspective
hat, in its current pioneering status, DT may be among the
ost complex therapies in medicine, mostly because it
nvolves complex decision-making across multiple disci-
lines, often requiring the creation of new knowledge, and
umerous steps in a spectrum of care from before the
peration through the end of life. We believe that team
rganization and operation contribute immensely and allow
hese challenging patients to survive through implantation,
ho would otherwise fail were it not for such a support
ystem.
imitations
tudy design, sample size, and uncertainties of applicability
re limitations, none of which are believed likely to undo
he major contributions of the study.
A study design using a historical control is not the
uality of a randomized, controlled trial. However, we
ought to limit as many disparities between the historical
nd present study as possible, save those that represent
dvancements by applying the same quality of decision-
aking and data collection, as well as applying similar
nclusion and exclusion criteria. Facilitating that is the con-
uct of the present study by the same experienced research
roup who were also major contributors to the historical
ata.
Sample size is certainly a limitation. A small number of
dded mortalities or adverse events has a greater impact on
small sample size than a large one. However, it would take
n unusually large deviation from current experience to
odify the data so significantly that it compromises the
mportant findings of this study. To put this into perspective,
his remains the largest single-center experience with DT in
field in which the numbers remain modest.
Applicability of this study to other centers is certainly a
imitation of any single-center study. However, we use
ractices that have been reduced to advanced guidelines
vailable to others and believe that our processes are repro-
ucible by others.
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CSPonclusions
lthough many challenges in the evolution of long-term DT
ith LVADs for advanced heart failure have been ad-
ressed, many hurdles remain.
It will be necessary for outcomes to improve beyond
EMATCH to transfer the sense of great potential held by
hose with pioneering spirit to those who are waiting for
vidence of substantial benefit to choose DT as a standard of
are from among the growing number of alternative thera-
ies. A field-wide goal of 50% 2-year survival seems rea-
onable at this stage.
In the future, DT will become less demanding as (1)
evices evolve,19,20 (2) management becomes standardized,
nd (3) patient selection improves first within current ad-
anced, REMATCH-like indications then followed by less-
dvanced heart failure as justified by outcomes. Until then,
issemination must be responsibly done among centers will-
ng to approach this with the necessary commitment, re-
ources, and patience.
It is not unreasonable to expect that DT may eventually
each outcomes on par with heart transplantation, especially
hen 10% to 15% mortality on the waiting list is added to
urrent posttransplant survival curves. It is worth remem-
ering that when heart transplantation was started, out-
omes were not too different than the early pioneering
xperiences with DT and that approximately 2 decades were
equired to evolve transplantation into the standard of care
f today.1,21
This experience of improving outcomes with DT should
ncourage continued pioneering with ventricular assist de-
ices for the treatment of advanced heart failure. For many
atients at or nearing end-stage heart failure, there is no
ther alternative at the present time that is equally
romising.
The authors acknowledge the valuable contributions made by
erry Heatley with data analysis. We thank Thoratec for providing
tatistical resources and access to updated REMATCH trial data.
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iscussion
r Cleveland (Denver, Colo). Jim, I congratulate you and your
oauthors at the Utah artificial heart program for achieving exem-
lary outcomes with a complex and challenging group of patients
ndergoing LVAD therapy as sole therapy for advanced heart
ailure. Again, Jim did a good job emphasizing and placing this
roup of patients and the results of the study in the context of the
act that these are critically ill patients. All had class IV congestive
eart failure for at least 90 days. All had an ejection fraction less
han 25%. All had a VO2 max less than 12 mL/kg/min, and most
mportant all had no other therapy (ie, heart transplantation). The
rinciple finding of the present study in this cohort of 23 patients
ndergoing DT in Utah is a 1-year survival of 77% versus 52% in
he surgically implanted destination group in the REMATCH trial.
articularly noteworthy is the subsequent 2-year survival of 77%
n Dr Long’s cohort versus only 30% in the REMATCH cohort.
If one considers the nature of this therapy for heart failure, therere 3 main mechanisms that could be offered to explain the
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Long et al Cardiopulmonary Support and Physiologymproved outcomes seen in your study. First is earlier patient
mplant. Obviously these are sick but not moribund patients, and
ou alluded to that, perhaps if their sodium was a little higher,
erhaps if their blood pressure was a little higher. Second is
mprovement in the HeartMate or LVAD technology itself. Third
s improvement in patient management. Which of these 3 to do you
elieve is most operant in providing for these results?
Dr Long. In this era I think patient management is the most
ritical step by which we can improve this field. Certainly as
evices improve we are going to see added reliability and dura-
ility, but we have not yet been able to identify that in the limited
umbers we’ve seen. Reduction in mortality because of device
ailure is largely the result of managing patients better through the
erioperative period. We think the reduction in infection, the first
eading cause of mortality in the REMATCH trial, is also largely
he result of infection, but clearly as devices improve, get smaller
ith percutaneous leads that are smaller, it will be much easier to
educe infections, much easier to implant these, and have a more
urable device, moving beyond 2-year devices into the 4 range.
atient selection is critical. Now we are constrained to the
EMATCH-like patients largely because of Centers for Medicare
nd Medicaid Services constraints and the regulatory approval
rocess. I think if we are going to do this effectively we have to
ove beyond that, but we really can’t move beyond that until we t
The Journal of Thoracicet some good results with those kinds of patients. I think it is
mportant for centers across this country to set targets of 50%
-year survivorship, and if we do achieve that across this field I
hink we earn the right to move to a less ill patient population
nalogous to those who were in the REMATCH trial.
Dr Cleveland. Second, as discussed in your article, and it’s
eally a well-written and clear article, DT has been offered only to
small number of patients. I think a reason for this is cost. Eric
ose and colleagues published subsequent cost data from the
EMATCH trial suggesting that with DT if the patient incurs
omplications perioperatively, particularly that of sepsis or bleed-
ng, the cost of this therapy increases to near-prohibitive levels. Do
ou have associated data? I know you didn’t present here today,
ut do you have data suggesting that with your improved outcomes
he cost of the therapy is less and therefore it may make this more
pproachable by many centers?
Dr Long. Your observation is right on. The destination field
eally didn’t begin picking up post-REMATCH until Centers for
edicare and Medicaid Services approval was in place, so that
ives you some indication how important reimbursement is to this.
n more recent studies yet to be released, we’re finding that we can
ecrease this to the $140,000 range and to the $130,000 range in
hose without complications.
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